Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)

被引：10

作者：

Lacy, Martha Q. ^{[1
]}

LaPlant, Betsy R. ^{[1
]}

Laumann, Kristina M. ^{[1
]}

Kumar, Shaji ^{[1
]}

Gertz, Morie A. ^{[1
]}

Hayman, Suzanne R. ^{[1
]}

Buadi, Francis ^{[1
]}

Dispenzieri, Angela ^{[1
]}

Lust, John A. ^{[1
]}

Kapoor, Prashant ^{[1
]}

Leung, Nelson ^{[1
]}

Russell, Stephen J. ^{[1
]}

Dingli, David ^{[1
]}

Gonsalves, Wilson I. ^{[1
]}

Fonseca, Rafael ^{[2
,3
]}

Bergsagel, P. Leif ^{[3
]}

Roy, Vivek ^{[4
]}

Sher, Taimur ^{[4
]}

Ailawadhi, Sikander ^{[4
]}

Chanan-Khan, Asher ^{[4
]}

Stewart, A. Keith ^{[3
]}

Reeder, Craig B. ^{[2
]}

Rajkumar, S. Vincent ^{[1
]}

Mikhael, Joseph R. ^{[2
]}

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Mayo Clin Arizona, Scottsdale, AZ USA

[3] Mayo Clin, Scottsdale, AZ USA

[4] Mayo Clin, Jacksonville, FL 32224 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

10.1182/blood.V124.21.304.304

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Paludo, Jonas
Mikhael, Joseph R.
LaPlant, Betsy R.
Halvorson, Alese E.
Kumar, Shaji
Gertz, Morie A.
Hayman, Suzanne R.
Buadi, Francis K.
Dispenzieri, Angela
Lust, John A.
Kapoor, Prashant
Leung, Nelson
Russell, Stephen J.
Dingli, David
Go, Ronald S.
Lin, Yi
Gonsalves, Wilson I.
Fonseca, Rafael
Bergsagel, P. Leif
Roy, Vivek
Sher, Taimur
Chanan-Khan, Asher A.
Ailawadhi, Sikander
Stewart, A. Keith
Reeder, Craig B.
Richardson, Paul G.
Rajkumar, S. Vincent
Lacy, Martha Q.
BLOOD, 2017, 130 (10) : 1198 - 1204
[2] Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM.
Schjesvold, Fredrik
Dimopoulos, Meletios A.
Beksac, Meral
Oriol, Albert
Lindsay, Jindriska
Liberati, Anna Marina
Galli, Monica
Robak, Pawel
Weisel, Katja
Larocca, Alessandra
Yagci, Munci
Vural, Filiz
Anderson, Larry D., Jr.
Kanate, Abraham Sebastian
Mendez, Eva Casal
Jiang, Ruiyun
Srinivasan, Shankar
Grote, Lara
Biyukov, Tsvetan Nikolov
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Cerchione, C.
Pareto, A. E.
Zacheo, I.
Di Perna, M.
Nappi, D.
Peluso, I.
Ferrara, K.
Pane, F.
Catalano, L.
HAEMATOLOGICA, 2018, 103 : S116 - S117
[4] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
Yee, Andrew J.
Laubach, Jacob P.
Campagnaro, Erica L.
Lipe, Brea C.
Nadeem, Omar
Friedman, Robb S.
Cole, Craig E.
O'Donnell, Elizabeth K.
Bianchi, Giada
Branagan, Andrew R.
Schlossman, Robert L.
Shapiro, Samantha J.
Harrington, Cynthia C.
Burke, Jill N.
Gammon, Marilyn T.
Lively, Kathleen J.
Reimonn, Cassandra A.
Andrade, Danielle X.
Redd, Robert
Lohr, Jens G.
Anderson, Kenneth C.
Richardson, Paul G.
Raje, Noopur S.
BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
[5] Activity of pomalidomide plus dexamethasone (Pom/dex) in dual lenalidomide/bortezomib refractory multiple myeloma (MM).
Lacy, M.
Gertz, M. A.
Hayman, S. R.
Dispenzieri, A.
Kumar, S.
Mikhael, J.
Stewart, A. K.
Allred, J.
Mandrekar, S. J.
Rajkumar, S. V.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[6] Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide
Oka, Satoko
Ono, Kazuo
Nohgawa, Masaharu
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2018, 43 (06) : 914 - 917
[7] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
David S. Siegel
Gary J. Schiller
Christy Samaras
Michael Sebag
Jesus Berdeja
Siddhartha Ganguly
Jeffrey Matous
Kevin Song
Christopher S. Seet
Giampaolo Talamo
Mirelis Acosta-Rivera
Michael Bar
Donald Quick
Bertrand Anz
Gustavo Fonseca
Donna Reece
William E. Pierceall
Weiyuan Chung
Faiza Zafar
Amit Agarwal
Nizar J. Bahlis
Leukemia, 2020, 34 : 3286 - 3297
[8] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Siegel, David S.
Schiller, Gary J.
Samaras, Christy
Sebag, Michael
Berdeja, Jesus
Ganguly, Siddhartha
Matous, Jeffrey
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Pierceall, William E.
Chung, Weiyuan
Zafar, Faiza
Agarwal, Amit
Bahlis, Nizar J.
LEUKEMIA, 2020, 34 (12) : 3286 - 3297
[9] MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Hofmeister, Craig C.
Siegel, David
Lonial, Sagar
Laubach, Jacob P.
Efebera, Yvonne A.
Vesole, David H.
Nooka, Ajay K.
Rosenblatt, Jacalyn
Raje, Noopur
Zaki, Mohamed H.
Hua, Ye
Li, Yan
Shah, Sheetal
Wang, Jianming
Anderson, Kenneth C.
BLOOD, 2013, 122 (21)
[10] MM-005: A PHASE 1 TRIAL OF POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Richardson, P.
Hofmeister, C.
Siegel, D.
Lonial, S.
Laubach, J.
Efebera, Y.
Vesole, D.
Nooka, A.
Rosenblatt, J.
Raje, N.
Zaki, M.
Hua, Y.
Shah, S.
Wang, J.
Anderson, K.
HAEMATOLOGICA, 2013, 98 : 97 - 98

← 1 2 3 4 5 →